SGLT2 inhibitor is kidney protective, even if eGFR <30 - PACE-CME

SGLT inhibitor is kidney protective even if eGFR

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
MinuteCE®
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
1.25 program credits
- Akshay S. Desai, MD
- John McMurray, MD
1.25 program credits
MinuteCE®
Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes
0.75 credits 3 episodes
- Gianluigi Savarese, MD
- James Burton, DM, FRCP
- Aaron Wong, MD
0.75 credits 3 episodes
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
MinuteCE®
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
0.75 program credits
- Gianluigi Savarese, MD
0.75 program credits
Summarizing multidisciplinary strategies: Where do we go from here?
Summarizing multidisciplinary strategies: Where do we go from here?
MinuteCE®
Summarizing multidisciplinary strategies: Where do we go from here?
0.75 program credits
- Gianluigi Savarese, MD
0.75 program credits